KA/EN
Register
Medicines reference
Search
Search
Active substance

Insulin glargine

Favourites

Long-acting insulin analogue. Registered in Georgia: 1 human medicine. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Insulin glargine
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.3 IU/kg
off-label
 Dog Diabetes Mellitus Subcutaneous 2 times daily
AAHA 2018
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
2018 AAHA Diabetes Management Guidelines for Dogs and Cats
Journal of the American Animal Hospital Association, 2018
0.25–0.5 IU/kg
off-label
 Cat Diabetes Mellitus Subcutaneous 2 times daily
AAHA 2018
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
2018 AAHA Diabetes Management Guidelines for Dogs and Cats
Journal of the American Animal Hospital Association, 2018
Before use

Safety information

Known Contraindications

  • Critical
    Hypersensitivity to insulin glargine or any product component is a contraindication.
    Source: EMA Sources: EMA
  • Warning
    Risk of hypoglycaemia (blood glucose below 3.0 mmol/l, 54 mg/dl): it seems more frequent in diabetic cats than in dogs, can be life-threatening and needs prompt treatment. Severe hypoglycaemia appears more frequent in cats receiving more than 6 U per cat. Use a syringe that matches the insulin concentration (a U-100 syringe for U-100 insulin).
    Sources: AAHA · ISFM

Known Drug Interactions

  • Major warning Dexamethasone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Prednisolone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Levothyroxine + Insulin glargine
    Starting or changing levothyroxine supplementation in a diabetic dog receiving insulin can alter the insulin requirement.
    Recommendation: Monitor glycaemic control frequently when starting levothyroxine.
Latin name
Insulin glargine
Georgian name
ინსულინი გლარგინი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
1 of 1 forms
Products
Lantus SoloStar
Human medicines in Georgia
Lantus, Lantus SoloStar, Toujeo Solostar
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Lantus SoloStar 100 U/ml, Solution

3 ml prefilled pen, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Chronic subcutaneous treatment of confirmed diabetes mellitus with exact Lantus SoloStar U-100; diabetic ketoacidosis, intravenous/intramuscular use and glargine U-300 are outside scope
7.4/10
Good
vetman assessment

Lantus SoloStar

100 U/ml, 3 ml prefilled pen, solution for injection, human medicine
Assessed clinical scopeDog · Chronic subcutaneous treatment of confirmed diabetes mellitus with exact Lantus SoloStar U-100; diabetic ketoacidosis, intravenous/intramuscular use and glargine U-300 are outside scope · Subcutaneous
Care settingVeterinarian-directed long-term home treatment with trained caregiver and structured glucose/clinical monitoring
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-044088 · Verified on 15 Oct 2026 Off-label use

A credible off-label canine insulin option when the patient is demonstrably controlled on U-100 glargine or standard choices are unsuitable. The exact pen is convenient for whole-unit dosing, but limited canine evidence and current preference for other first-line formulations keep it situational within an overall good score.

Regulatory and scientific credibility8.5/10

The exact Sanofi U-100 SoloStar presentation has a current transparent central EMA dossier and current Georgian and EU human authorisations. Direct dog/cat glargine evidence and current consensus support veterinary use, but no dog/cat authorisation applies and veterinary use remains off-label.

Clinical efficacy6.5/10

Two small prospective canine studies show that twice-daily U-100 glargine can improve clinical and glycaemic control, but sample sizes are limited and one study judged success lower than commonly reported with other insulins. Current canine guidance recommends porcine lente or NPH as routine first choices and discusses U-300, not this U-100 product, as a basal alternative.

Safety and tolerability7.0/10

Hypoglycaemia is the important dose-dependent hazard, but it is well characterised and usually manageable with conservative titration, home glucose or CGM, clinical review and a written emergency plan. Wrong-product/concentration errors, blocked or reused needles, dose stacking and failure to recognise remission or reduced intake can cause serious harm.

Clinical practicality7.5/10

The clear solution needs no resuspension, and the prefilled pen gives repeatable whole-unit doses with little preparation; current canine guidance commonly rounds down to a whole unit. Twice-daily lifelong injections, priming, new needles, monitoring and four-week in-use disposal remain meaningful burdens, and very small dogs may still need a finer device.

Full-course cost-effectiveness-

Current comparable local full-course prices, needle costs and presentation wastage were not verified.

Important safety and use flags

  • This score covers chronic SC treatment of confirmed diabetes only. Do not use this pen IV or IM, do not transfer the score to glargine U-300, and do not use it as the routine insulin for DKA; concentrations and time-action profiles are not interchangeable.
  • Lantus SoloStar is a human medicine and veterinary use is off-label. Confirm the exact U-100 product before every injection; similarly named U-300 glargine, other insulin types and U-40 veterinary insulin require different devices and dosing decisions.
  • The SoloStar dial delivers whole units only. Never estimate a half-click and never withdraw insulin from the pen with a syringe. If the prescribed dose or adjustment is 0.5 U or another fraction, use a veterinarian-selected presentation/device that can deliver it accurately.
  • Use a new compatible needle for every injection, perform the labelled safety test, verify flow and remove the needle after use. Reused or blocked needles, air, leakage or storing the pen with a needle attached can cause underdose, overdose or contamination.
  • Confirm persistent diabetes rather than isolated stress hyperglycaemia, particularly in cats. Establish baseline weight, urinalysis/culture as indicated, ketones, fructosamine or glucose data and relevant comorbidity; investigate obesity, hypersomatotropism, hyperadrenocorticism, pancreatitis and diabetogenic medicines when control is poor.
  • Titrate conservatively from serial clinical and glucose data, not one spot value. Track thirst, urination, appetite, body weight, home glucose or CGM and periodic curves/fructosamine; avoid rapid upward changes and reassess technique, diet and concurrent disease before calling the patient insulin resistant.
  • Have a written hypoglycaemia plan. Weakness, ataxia, tremor, disorientation, seizures or collapse require immediate glucose support and urgent veterinary care; asymptomatic low readings, reduced intake, vomiting, increased activity or suspected remission require prompt dose review rather than automatic continuation.
  • For cats, do not promise remission or claim that glargine is uniquely superior. Remission depends on early safe control, diet, weight and comorbidity, may not occur, and can relapse; monitor for return of polyuria, polydipsia, weight loss, hyperglycaemia or ketones after insulin is stopped.
  • Do not mix or dilute Lantus. Use only clear colourless particle-free solution. Store unopened pens at 2–8 C without freezing; keep the in-use pen below 30 C away from heat/light and discard after four weeks even if insulin remains.
  • Review glucocorticoids, progestogens and other medicines or diseases that antagonise insulin, plus agents that may mask or amplify hypoglycaemia. Pregnancy, lactation, immature age and major renal/hepatic disease require an explicit individual benefit-risk and monitoring plan.
Assessment sources
  1. Lantus SoloStar EMA2026
  2. Lantus SoloStar GE register2026
  3. iCatCare feline diabetes 20252025
  4. AAHA feline diabetes 20262026
  5. AAHA canine diabetes 20262026
  6. Feline glargine comparison2009
  7. Feline intensive insulin RCT2014
  8. Feline glargine diet RCT2008
  9. Feline glargine real-world cohort2024
  10. Canine glargine six-month trial2012
  11. Canine glargine prospective trial2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Chronic subcutaneous treatment of confirmed diabetes mellitus with exact Lantus SoloStar U-100; diabetic ketoacidosis, intravenous/intramuscular use and glargine U-300 are outside scope
7.4/10
Good
vetman assessment

Lantus SoloStar

100 U/ml, 3 ml prefilled pen, solution for injection, human medicine
Assessed clinical scopeCat · Chronic subcutaneous treatment of confirmed diabetes mellitus with exact Lantus SoloStar U-100; diabetic ketoacidosis, intravenous/intramuscular use and glargine U-300 are outside scope · Subcutaneous
Care settingVeterinarian-directed long-term home treatment with trained caregiver and structured glucose/clinical monitoring
vetman score 7.4/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-044088 · Verified on 15 Oct 2026 Off-label use

An effective, common off-label feline insulin with substantial direct evidence, but not a uniquely superior remission product. The exact SoloStar presentation loses important practical value because it cannot deliver half-unit changes; use it only when the prescribed dose is a whole unit and choose another validated device when finer titration is needed.

Regulatory and scientific credibility8.5/10

The exact Sanofi U-100 SoloStar presentation has a current transparent central EMA dossier and current Georgian and EU human authorisations. Direct dog/cat glargine evidence and current consensus support veterinary use, but no dog/cat authorisation applies and veterinary use remains off-label.

Clinical efficacy8.0/10

Multiple direct studies and current guidelines support twice-daily U-100 glargine as an effective common feline insulin. Early small comparisons reported strong control and remission, but newer consensus finds no compelling proof that one insulin is universally best and remission remains dependent on early control, diet, comorbidity and monitoring rather than brand alone.

Safety and tolerability7.0/10

Hypoglycaemia is the important dose-dependent hazard, but it is well characterised and usually manageable with conservative titration, home glucose or CGM, clinical review and a written emergency plan. Wrong-product/concentration errors, blocked or reused needles, dose stacking and failure to recognise remission or reduced intake can cause serious harm.

Clinical practicality5.5/10

The clear solution and prefilled pen are simple when a whole-unit dose is appropriate, but the exact device cannot deliver common 0.5-U feline adjustments. A half-click is not valid and the label prohibits syringe withdrawal from the pen; cats needing fractional changes require another presentation/device. Twice-daily injections, priming, new needles and close monitoring add continuing caregiver burden.

Full-course cost-effectiveness-

Current comparable local full-course prices, needle costs and presentation wastage were not verified.

Important safety and use flags

  • This score covers chronic SC treatment of confirmed diabetes only. Do not use this pen IV or IM, do not transfer the score to glargine U-300, and do not use it as the routine insulin for DKA; concentrations and time-action profiles are not interchangeable.
  • Lantus SoloStar is a human medicine and veterinary use is off-label. Confirm the exact U-100 product before every injection; similarly named U-300 glargine, other insulin types and U-40 veterinary insulin require different devices and dosing decisions.
  • The SoloStar dial delivers whole units only. Never estimate a half-click and never withdraw insulin from the pen with a syringe. If the prescribed dose or adjustment is 0.5 U or another fraction, use a veterinarian-selected presentation/device that can deliver it accurately.
  • Use a new compatible needle for every injection, perform the labelled safety test, verify flow and remove the needle after use. Reused or blocked needles, air, leakage or storing the pen with a needle attached can cause underdose, overdose or contamination.
  • Confirm persistent diabetes rather than isolated stress hyperglycaemia, particularly in cats. Establish baseline weight, urinalysis/culture as indicated, ketones, fructosamine or glucose data and relevant comorbidity; investigate obesity, hypersomatotropism, hyperadrenocorticism, pancreatitis and diabetogenic medicines when control is poor.
  • Titrate conservatively from serial clinical and glucose data, not one spot value. Track thirst, urination, appetite, body weight, home glucose or CGM and periodic curves/fructosamine; avoid rapid upward changes and reassess technique, diet and concurrent disease before calling the patient insulin resistant.
  • Have a written hypoglycaemia plan. Weakness, ataxia, tremor, disorientation, seizures or collapse require immediate glucose support and urgent veterinary care; asymptomatic low readings, reduced intake, vomiting, increased activity or suspected remission require prompt dose review rather than automatic continuation.
  • For cats, do not promise remission or claim that glargine is uniquely superior. Remission depends on early safe control, diet, weight and comorbidity, may not occur, and can relapse; monitor for return of polyuria, polydipsia, weight loss, hyperglycaemia or ketones after insulin is stopped.
  • Do not mix or dilute Lantus. Use only clear colourless particle-free solution. Store unopened pens at 2–8 C without freezing; keep the in-use pen below 30 C away from heat/light and discard after four weeks even if insulin remains.
  • Review glucocorticoids, progestogens and other medicines or diseases that antagonise insulin, plus agents that may mask or amplify hypoglycaemia. Pregnancy, lactation, immature age and major renal/hepatic disease require an explicit individual benefit-risk and monitoring plan.
Assessment sources
  1. Lantus SoloStar EMA2026
  2. Lantus SoloStar GE register2026
  3. iCatCare feline diabetes 20252025
  4. AAHA feline diabetes 20262026
  5. AAHA canine diabetes 20262026
  6. Feline glargine comparison2009
  7. Feline intensive insulin RCT2014
  8. Feline glargine diet RCT2008
  9. Feline glargine real-world cohort2024
  10. Canine glargine six-month trial2012
  11. Canine glargine prospective trial2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Insulin glargine100 IU/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Sanofi · France
Registration
Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
№ რ-044088
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK Yes, human
№ PLGB044250816, PLPI057260021, PLPI151842113, PLPI151842114
Verified on: 16 Oct 2026
 US Yes, human
№ BLA021081
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified The pen delivers 1–80 U in one-unit steps and is SC-only. It cannot deliver 0.5 U; never estimate a half-click or withdraw solution from the pen with a syringe. When a calculated veterinary dose is fractional, use another validated presentation or device. Do not mix or dilute. Use a new compatible needle and perform the labelled safety test before every injection.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗